OKYO News & Events

The deal range was $1.80-$1.90. Piper Sandler acted as sole book running manager for the offering.

Okyo Pharma Limited announced that it intends to offer to sell its ordinary shares in an underwritten public offering. All of the ordinary shares are to be sold by the company. The company intends to use the net proceeds from the offering primarily for clinical development of its product candidates, general corporate purposes and working capital. Piper Sandler & Co. is acting as the sole book-running manager for the offering.

OKYO Pharma announced the appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer. Dr. Mantelli led the clinical development, regulatory approval, and global medical strategy of Oxervate at Dompe farmaceutici S.p.A.